Navigation Links
Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
Date:9/15/2008

BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer. UNBS 5162 was discovered by Unibioscreen and is currently in Phase I trials in the United States in cancer patients with advanced solid tumors or lymphoma.

"This is an important milestone for Drais as we focus on building a portfolio of novel therapeutics," said Dr. Donna L. Tempel, president and chief executive officer of Drais Pharmaceuticals. "Partnering with innovative companies like Unibioscreen is an important step towards implementing our strategy of in-licensing and developing novel therapeutic treatments that meet unmet medical needs."

Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants exclusive rights to Drais to develop and commercialize UNBS 5162 worldwide.

Christiane Verhaegen, chief executive officer and chief financial officer of Unibioscreen commented: "Unibioscreen's deal with Drais is a key milestone for both the development of the drug candidate and for the company as it provides validation of Unibioscreen's promising pipeline of potential cancer treatments in addition to monetary benefits. We are confident that Drais' experienced team will maximize the progression of UNBS 5162 and believe this agreement will provide excellent value for both partners." Denis Biju-Duval, Head of ING Belgium Corporate Investments added: "The agreement illustrates the ability of Unibioscreen to successfully exploit its unique technology and know-how. Unibioscreen will continue to innovate in the oncology sector."

About UNBS 5162

UNBS 5162 is a novel anti-cancer naphthalimide discovered, patented & developed by Unibioscreen. In preclinical studies, UNBS 5162 has shown antitumor activity in several cancer models and is currently in a Phase I trial.

UNBS 5162 is anti-angiogenic in vivo, and has been shown to decrease CXCL chemokine expression in experimental prostate cancers. UNBS 5162 is a pan- antagonist of CXCL chemokines when administered in vitro chronically at 1 M, which is a drug concentration compatible with the doses used in vivo. The mode of action, as assessed by a National Cancer Institute comparative screen, appears to be unique.

In an orthotopic model of human refractory prostate cancer, UNBS 5162 has been demonstrated to function synergistically with the anti-tumor effects of taxol. The drug also increases the therapeutic benefits of radiotherapy.

The Phase I trial is currently being conducted under the supervision of Daniel Von Hoff, M.D. at TGen Clinical Research Services at The Virginia G. Piper Cancer Center at Scottsdale Healthcare, Mayo Clinic Scottsdale and the University of Arizona Cancer Center Tucson.

About Unibioscreen S.A.

Unibioscreen is a specialist oncology drug discovery and development company, working on novel, first-in-class compounds, with two blockbuster- potential drugs candidates starting clinical development.

Unibioscreen's core business is the identification and development of new chemical entities for the targeted treatment of cancer and its metastases. The company's focus is on cytotoxic/cytostatic chemotherapeutics that kill apoptosis-resistant and multidrug resistant cancer cells, and anti-migratory drug candidates that fight metastases. Most of Unibioscreen's drug candidates are derived from molecules observed in natural plants or marine invertebrates. Unibioscreen will continue to develop novel compounds in the clinic.

More information is available on http://www.unibioscreen.com

About Drais Pharmaceuticals, Inc.

Drais Pharmaceuticals, Inc. is a privately held, drug development company dedicated to the in-licensing, development and commercialization of novel therapeutic treatments that address unmet medical needs, providing significant benefits over currently available therapies.

Formed in September 2007, Drais completed a Series A financing round in January 2008 from lead investors, InterWest Partners (Menlo Park, CA) and Sutter Hill Ventures (Palo Alto, CA). The Drais management team consists of highly experienced individuals with a successful track record in the pharmaceutical industry. Prior to forming Drais, the management team founded AkaRx, Inc. Drais is based in Bridgewater, New Jersey.
For more information, please visit: http://www.draispharma.com.

CONTACT:

Drais Pharmaceuticals, Inc. Unibioscreen S.A.

James F. Lynch, PhD Christiane Verhaegen

Chief Business Officer Chief Executive Officer

+ 1 (908) 895-1216 +32 476 98 10 78

Dimitri Dimitriou

Chief Business Officer

+44 794 929 3222


'/>"/>
SOURCE Drais Pharmaceuticals, Inc. and Unibioscreen S.A.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Provides Update on Iloperidone
2. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
3. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
4. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
5. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... June 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... innovative inhaled drugs, announced today that it was added ... reconstituted its comprehensive set of U.S. and global ... is an important milestone for Pulmatrix," said Chief Executive ... awareness of our progress in developing drugs for crucial ...
Breaking Medicine Technology:
(Date:6/26/2016)... Charlotte, NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind ... able to be personalized through a fitness app. The fitness app plans to fix the ... solutions currently only offer a one size fits all type program , They ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may ... to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To ... for healthy coping following a traumatic event. , Trauma sufferers tend to feel a ...
(Date:6/24/2016)... ... , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys ... peers for this recognition are considered among the top 2 percent of lawyers practicing ... members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. ...
Breaking Medicine News(10 mins):